Summary page of the EQA programme
The programme is focused on external quality assessment of testing of mutations of clinically most important genes
relevant to anti-EGFR therapy in colorectal carcinoma - KRAS, NRAS, BRAF. Participants are expected to identify and describe
mutations, they can choose any combination of KRAS, NRAS, BRAF testing.
Complete description you can find in the EQA Plan 2023 (namely page 30).
Short description is available in the CRC 2023 flyer.
|European Society of Pathology Quality Assurance Foundation|
Barastraat 6, 1070 Brussels, Belgium
|SEKK s.r.o., EHK Division|
Arnošta z Pardubic 2605, 530 02 Pardubice, Czech Republic
|Accreditation:||Certificate of accreditation|
The laboratories from all countries are welcome to participate in CRC programme.
We believe that these examples will give you a good insight.
|Public part of the evaluation|
(EQA round CRC2/22)
|Private part of the evaluation|
(anonymised and shortened examples from the EQA round CRC2/22)
Confirmation of attendance
|Certificate of approval||Result sheet|
To view the latest finished EQA round (CRC2/22) please click here.
Last update: 19.11.2022